Genesis HealthCare System Partners with Medicom Health to Lower Medication Costs for Patients

New Electronic Medical Record Add-On Automates the Delivery of Rx Discounts at Enterprise Scale

October 6, 2020

Genesis HealthCare System has chosen to deploy Medicom Health’s Rx Savings Assistant® solution as part of its ongoing commitment to improving medication adherence and reducing patient readmissions.

Genesis HealthCare System is an integrated health care delivery system and the largest health care provider in its six-county region of southeastern Ohio. Their mission is to provide compassionate, quality health care.

Medicom Health’s new Rx Savings Assistant® software is a simple way for health systems to instantly increase prescription fills by making them more affordable for more patients. This technology supplements other patient assistance programs and leverages their electronic medical record (EMR) investment.

The solution is a plug-in module for EMRs like Epic and Cerner. It listens for new prescriptions and searches external databases for matching discount offers from various partners. Medicom Health’s technology adds brand name and generic savings offers into the patient records automatically. The discounts are easily available on the printed paperwork handed to each qualified patient at discharge. Because the system runs behind the scenes, it does not alter physician workflow or influence prescribing.

Pharmaceutical manufacturers already provide discounts and free trial offers through DTC channels, but most patients don’t take advantage of them for various reasons, including awareness and access issues. This clinical channel is both more effective and more efficient.

“Reducing patients’ medication costs improves their adherence and ultimately their health,” says Tony Huth, President of Medicom Health. “We can move the needle on adherence because of the volume and quality of our discounts, and friction-free delivery. Every qualified patient automatically has effortless access to discounts, potentially for every prescription.”

“We are always looking for ways to improve access to medications for our patients, especially given the rising rate of unemployment,” said Linda Suplee, population health strategist at Genesis HealthCare System. Helping patients afford their medications ultimately improves outcomes and reduces readmission rates.”

Increased adherence results in many benefits to patients and providers, including better outcomes, patient satisfaction, pharmacy revenues, and more. Hospitals in the United States are accountable for resulting readmission costs, poor outcomes, and low HCAHP scores.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”